Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The low frequency of the APOE ∊4 allele may suggest a low genetic risk of Hakka population for cardiovascular disease, Alzheimer's disease, and other diseases.
|
30508003 |
2020 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Inherited abnormalities in apolipoprotein E (ApoE) or low-density lipoprotein receptor (LDLR) function result in early onset cardiovascular disease and death.
|
30654068 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
|
30598326 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Age and apolipoprotein E (ApoE) are the mightiest risk factors for dementia and cardiovascular diseases, but the underlying mechanisms remain unclear.
|
30232753 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The apolipoprotein E (APOE) gene ɛ4 allele is a risk factor for Alzheimer's disease and cardiovascular disease.
|
31381519 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We found in separate models that women were significantly more likely to have AD and CVD pathology than men, and men were more likely to have "pure" Lewy Body disease, in models adjusted for age at death, education, race, and the APOE-e4 allele.
|
31128096 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E gene polymorphism and the risk of cardiovascular disease and type 2 diabetes.
|
31521122 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Low levels of HDL cholesterol, adjusted for ApoE and the above mentioned variables, associated with higher prevalence of CVD (aOR=1.35, 95%CI 1.00, 1.83) and all-cause mortality (aHR=1.42, 95%CI 1.14, 1.78).
|
31585002 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
APOE genotype was associated with baseline lipid fractions (e.g. mean difference(95%CI) in LDL(mg/dL) for ε2 versus ε33: -17.1(-18.1-16.0), and ε4 versus ε33: +5.7(4.8;6.5)), but the association between APOE and mortality was unaltered after adjustment for baseline LDL or cardiovascular disease.
|
31356640 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Genome-wide association (GWAS) and whole-genome sequencing (WGS) studies on centenarians pointed toward the inclusion of the apolipoprotein E (<i>APOE</i>) polymorphisms ε2 and ε4, as implicated in the attainment of extreme longevity, which refers to their effect in age-related Alzheimer's disease (AD) and cardiovascular disease (CVD).
|
30884759 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Although apolipoprotein E4 (ApoE4), one of the isoforms coded by a polymorphic APOE gene, has been widely recognized as a risk factor for cardiovascular diseases and as an immunoinflammatory factor, less is known regarding how ApoE4 affects atherosclerosis in periodontitis patients.
|
30503976 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E (APOE) gene polymorphism is associated with neurodegenerative and cardiovascular diseases.
|
31625294 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Therefore, in this narrative review, we discuss how omega-3 fatty acid intake and physical activity may modify the impact of ApoE ɛ4 on AD and CVD risk.
|
30321297 |
2019 |
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that epigenetic modification of ABCG1 and APOE may play a role in the pathway from disturbed blood lipid levels to the development of cardiovascular diseases.
|
31823830 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We estimated the risk of dementia in relation to SBP variation measured at different time windows (i.e., at least 0, 5, 10, and 15 years) prior to dementia diagnosis, with adjustments for age, sex, education, apolipoprotein E (APOE) genotype, vascular risk factors, and history of cardiovascular disease.
|
31714941 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
The future of apolipoprotein E mimetic peptides in the prevention of cardiovascular disease.
|
31157629 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The APOE4 allele is not only the strongest genetic risk factor for AD, it also affects risk for cardiovascular disease, stroke, and other neurodegenerative disorders.
|
30844401 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
APOE differentially affects type and timing of CVD-related neuropathology.
|
30321502 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Due to the presence of different APOE isoforms in human population, understanding APOE's role in pathological processes represents not only a challenge, but a demand for further development of therapeutic strategies for cardiovascular diseases.
|
30213474 |
2018 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
The apolipoprotein E-deficient (apoE-/-) mouse model has advanced our understanding of cardiovascular disease mechanisms and experimental therapeutics.
|
29166645 |
2018 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
LSR gene is located upstream of APOE, an important risk factor for cardiovascular disease (CVD).
|
29178324 |
2018 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We found that higher DNA methylation levels in the promoter region of APOE increase the odds of dementia and AD, but not CVD.
|
29509901 |
2018 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Abbreviations: PVAT: perivascular adipose tissue; ApoE: apolipoprotein E deficient mouse strain; Control: C57Bl/6J mouse strain; PTA: 0.3% phosphotungstic acid; microCT: micro-computed tomography; CV: cardiovascular; CVD: cardiovascular disease; IQR: interquartile range; PPARγ: peroxisome proliferator activated receptor - gamma; VV: vasa vasorum; 3D: three dimensional.
|
29956579 |
2018 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Different isoforms of ApoE have been associated with susceptibility to various diseases including Alzheimer's and cardiovascular diseases.
|
30496280 |
2018 |